ALK-Abelló A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKBLF research report →
Price Chart
About the company
Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe, North America, and other international regions. These offerings include immunotherapy products delivered through injections, sublingual drops, and oral tablets, designed to address various allergies such as those caused by house dust mites, grass, tree, ragweed, and Japanese cedar.
- CEO
- Peter Halling
- IPO
- 2009
- Employees
- 2,721
- HQ
- Horsholm, CR, DK
Get TickerSpark's AI analysis on AKBLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.63B
- P/E
- 36.22
- Fwd P/E
- 5.66
- PEG
- 1.04
- P/S
- 7.06
- P/B
- 7.05
- EV/EBITDA
- 21.36
- Div Yield
- 0.77%
- Gross Margin
- 67.76%
- Op Margin
- 26.73%
- Net Margin
- 19.51%
- ROE
- 20.45%
- ROIC
- 16.25%
Latest fiscal year · YoY change
- Revenue
- $6.30B+13.7%
- Gross Profit
- $4.15B+16.8%
- Op Income
- $1.66B
- Net Income
- $1.19B+46.5%
- EPS
- $5.41+47.0%
- OCF Growth
- +49.5%
- FCF Growth
- +1808.3%
- 52W High
- $40.65
- 52W Low
- $28.95
- 50D MA
- $39.18
- 200D MA
- $36.27
- Beta
- 0.71
- RSI (14)
- 19
- Avg Volume
- 25
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the AKBLF Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 60.1%
- Shares Outstanding
- 201.33M
- Float Shares
- 120.96M
Our AKBLF coverage
Recent articles, reports, and earnings notes.
No research on AKBLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKBLF report →ALK-Abelló A/S (AKBLF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 20
ALK-Abelló A/S (AKBLF) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 4
ALK-Abelló A/S (AKBLF) Shareholder/Analyst Call Transcript
seekingalpha.com · Mar 16
ALK-Abelló A/S (AKBLF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 20
Invitation to the presentation of ALK's annual report 2025 on Friday, 20 February 2026
globenewswire.com · Feb 13
ALK-Abelló A/S (OTC:AKBLF) Trading Up 1.8% – What’s Next?
defenseworld.net · Dec 31
ALK-Abelló A/S (AKBLF) Q3 2025 Earnings Call Transcript
seekingalpha.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.